Evofem Biosciences (EVFM) Proxy Filing summary

Executive summary

• The proxy filing details a proposed merger where Evofem Biosciences will become a wholly owned subsidiary of Aditxt, Inc., with the merger expected to close in the second half of 2025, subject to shareholder and regulatory approvals.

• Evofem common shareholders will receive a pro rata cash payment totaling $1.8 million, while Series E-1 and G-1 preferred shareholders will receive Aditxt Series A-2 Preferred Stock; all options will be canceled without payment.

• The merger is structured to address Evofem’s financial challenges, provide liquidity to shareholders, and leverage Aditxt’s resources for future growth.

• The board recommends voting in favor of the merger and adjournment proposals, and has entered into support agreements with key investors to secure votes.

Voting matters and shareholder proposals

• Shareholders are asked to approve the merger agreement and, if necessary, authorize adjournment of the meeting to solicit additional proxies.

• Approval requires a majority of the combined voting power of common and preferred shares, with abstentions and broker non-votes counted as votes against.

• Support agreements with major investors restrict transfer of shares and require votes in favor of the merger.

• Dissenting shareholders may seek appraisal rights under Delaware law.

Board of directors and corporate governance

• Post-merger, the surviving company’s officers will be Saundra Pelletier (CEO) and Ivy Zhang (CFO); directors will be Saundra Pelletier, Amro Albanna, and Lisa Rarick.

• The current board is divided into three classes, with independent directors and committees for audit, compensation, and governance.

• The board has recommended the merger as fair and in the best interests of shareholders.